Frontiers in Cellular and Infection Microbiology · Nov 16, 2026

Clinical evaluation of a risk-stratified screening strategy for opportunistic cervical cancer detection using primary human papillomavirus (HPV) E6/E7 mRNA testing with HPV 16 and 18/45 genotyping and reflex cytology

By Jiajia Wang, Jie Dong, Yinjian Zhou et al.

Objectives: To evaluate an opportunistic cervical cancer screening strategy using primary HPV E6/E7 mRNA assay (Aptima HPV, AHPV) screening with HPV 16 18/45 genotyping (AHPV-GT) and reflex cytology against the 2019 American Society for Colposcopy and Cervical Pathology (ASCCP) risk-based management guidelines. Methods: A total of 80,806 women aged 25–65 years underwent primary screening with AHPV and cytology co-testing. AHPV-positive women underwent AHPV-GT. Colposcopy with biopsy was performed when indicated. Four triage strategies were compared after an initial AHPV-positivity result: Strategy 1 (AHPV-GT with reflex cytology for the 11 other hrHPV genotypes); Strategy 2 (AHPV-GT and cytology for all AHPV-positive women); Strategy 3 (AHPV-GT alone); and Strategy 4 (cytology alone). Results: The overall hrHPV positivity rate was 13.6%, including 2.6% for AHPV-GT and 11.0% for other hrHPV genotypes. Among women positive for other hrHPV genotypes, those with atypical squamous cells of undetermined significance or worse (≥ ASC-US) had a higher immediate cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) risk than those with negative for intraepithelial lesion or malignancy (NILM) cytology (5.78% vs. 1.28%; P < 0.001); the former (≥ ASC-US) exceeded the 4.0% referral threshold. For CIN grade 2 or worse (CIN2+) detection, Strategies 1 and 2 had significantly higher sensitivity (80.8% vs. 58.9%, P < 0.001), a higher negative predictive value (NPV, 99.8% vs. 99.5%), and a higher Youden's index (0.761 vs. 0.555) than Strategy 4, and identified 37.1% more CIN2+ cases and 34.2% more CIN3+ cases, although they required 37.5% more colposcopies (4,494 vs. 3,268) than Strategy 4. Among cytology-containing strategies, Strategy 1 required the fewest cytology tests (11.0%; 8,882/80,806), corresponding to 81.1% of the number required by Strategies 2 and 4 (13.6%; 10,955/80,806), and it also required the fewest cytology tests per identified CIN2+ and CIN3+ case (11.2 and 17.8, respectively). Conclusions: Primary AHPV screening with AHPV-GT and reflex cytology appears to be a clinically effective, cytology-sparing strategy for opportunistic cervical cancer screening and aligns with the 2019 ASCCP risk-based management guidelines; however, verification bias arising from classifying women without histological verification as disease-free warrants caution when interpreting prevalence, risk estimates, and diagnostic performance.

The paperJournal siteBiomarkers

AgingResearch.News